Dr. Herbert Fritsche - Chief Scientific Advisor

Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas MD Anderson Cancer Center for 41 years.

Dr. Fritsche served as an invited consultant/advisor to the Food and Drug Administration, the National Cancer Institute, the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, the Editorial Board of six international scientific journals, and as a consultant to many major international diagnostic companies. Previously, he served on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center.

His awards include the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry, the Abbott-ISOBM Award for Outstanding Research in Oncology, the Morton K Schwartz Award for Outstanding Achievements in the field of Cancer Diagnostics from the American Association for Clinical Chemistry ("AACC"), the Carl Jolliff Award for Lifetime Achievements in Immunology and Immunodiagnostics from the Immunology Division of the AACC, the Morton K Schwartz Award for significant contributions to the development of cancer diagnostics from the New York Metro Division of the AACC, the Outstanding Clinical Chemist Award by the Texas Section of the AACC, the National Award for Contributions in Education by the AACC, the Dean's Excellence Award from the University of Texas Graduate School of Biomedical Science, and the Distinguished Scientist Award from the Clinical Ligand Assay Society ("CLAS").

Dr. Fritsche has served as President of the CLAS and various national committees for both the CLAS and AACC. He is a Fellow of the National Academy of Clinical Biochemistry.

He has published over 200 peer-reviewed scientific papers, invited articles and book chapters, and participated in the validation and FDA clearance process for many commercial serum cancer markers currently in use in the United States. Dr. Fritsche holds three patents and two patents pending.